phenoxyacetic acid

We are phenoxyacetic acid CAS:122-59-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:phenoxyacetic acid
CAS.NO:122-59-8
Synonyms:phenoxyacetic acid
2-phenoxyacetic acid
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 285.0±0.0 °C at 760 mmHg
Melting Point 98-100 °C(lit.)
Molecular Formula C8H8O3
Molecular Weight 152.147
Flash Point 115.1±13.3 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.541
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of 2,4-Dichlorophenoxyacetic acid(CAS:94-75-7) and Butyl 2,4-dichlorophenoxyacetate(CAS:94-80-4).

phenoxyacetic acid


Related News: Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.3-(9-phenyl-carbazol-3-yl)-9H-carbazole CAS:1060735-14-9 This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. N- [5-bromometil-4- (4-fluorofenil) -6-isopropilpirimidina-2-il] -N-metilmetano sulfonamida CAS:799842-07-2 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.2-Isopropylthioxanthone This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
2-Cyano-3,5-difluoropyridine View Details
(6S)​-​5-​Azaspiro[2.4]​heptane-​5,​6-​dicarboxylic acid 5-​(1,​1-​dimethylethyl) ester potassium salt View Details
5-Bromovaleric acid View Details
2-Bromo-6-methoxypyridine manufacturer 2-Chloro-1-((3-fluorobenzyl)oxy)-4-nitrobenzene manufacturer 4-Fluoro-3-methylaniline manufacturer 2-Bromo-3-fluoro-5-methylpyridine manufacturer 2′-Deoxyuridine 5′-mono-phos-phate disodium salt manufacturer